Determination of a Human Hepatic Microsomal Scaling Factor for Predicting in Vivo Drug Clearance

Overview

Journal Pharm Res

Specialties Pharmacology
Pharmacy

Date 2006 Mar 1

PMID 16505976

Citations 20

Authors

Nancy Hakooz

Kiyomi Ito

Helen Rawden

Helen Gill

Lynn Lemmers

Alan R Boobis

Robert J Edwards

David J Carlile

Brian G Lake

J Brian Houston

Affiliations

Soon will be listed here.

Abstract

Purpose: To determine a microsomal scaling factor for human liver suitable for prediction of in vivo drug clearance from in vitro data and to explore the role of inter-liver variability in this factor on the reported underprediction from microsomal parameters.

Methods: Cytochrome P450 (henceforth P450) content in whole homogenates and microsomes from 38 donor livers was used to determine a microsomal scaling factor. In a subset (n = 20) of these preparations, individual P450 enzymes were examined by Western blotting and selective probe activities were determined.

Results: The scaling factor from 38 livers averaged 40 mg microsomal protein per gram liver with a coefficient of variation of 31%. Western blotting experiments indicated that there was no P450 enzyme-specific trend in the distribution of individual P450 enzymes in liver microsomes relative to whole homogenate. Predictions based on an average scaling factor resulted in a satisfactory prediction of intrinsic clearance of three benzodiazepines similar to that obtained using individual factors for the same livers.

Conclusion: A value for human liver microsomal scaling of 40 mg microsomal protein per gram liver has been established. The reason for underprediction previously reported for 52 different drug substrates was not the use of an incorrect value for the scaling factor.

Citing Articles

Prediction of Pharmacokinetics for CYP3A4-Metabolized Drugs in Pediatrics and Geriatrics Using Dynamic Age-Dependent Physiologically Based Pharmacokinetic Models.

Han J, Zhang Z, Liu X, Yang H, Liu L Pharmaceutics. 2025; 17(2).

PMID: 40006581 PMC: 11860008. DOI: 10.3390/pharmaceutics17020214.

Inhibition of Tacrolimus Metabolism by Cannabidiol and Its Metabolites In Vitro.

So G, Lu J, Cheng Y, Gisch D, Koyama S, Ferreira R Clin Transl Sci. 2025; 18(2):e70152.

PMID: 39921332 PMC: 11806196. DOI: 10.1111/cts.70152.

Predicting Clearance with Simple and Permeability-Limited Physiologically Based Pharmacokinetic Frameworks: Comparison of Well-Stirred, Dispersion, and Parallel-Tube Liver Models.

Nagar S, Parise R, Korzekwa K Drug Metab Dispos. 2024; 52(10):1060-1072.

PMID: 39084881 PMC: 11409860. DOI: 10.1124/dmd.124.001782.

Metabolic Stability and Metabolite Identification of N-Ethyl Pentedrone Using Rat, Mouse and Human Liver Microsomes.

Godoi A, Antunes N, Cunha K, Martins A, Huestis M, Costa J Pharmaceutics. 2024; 16(2).

PMID: 38399311 PMC: 10893277. DOI: 10.3390/pharmaceutics16020257.

The metabolism and pharmacokinetics of the bacterial β-glucuronidase inhibitor UNC10201652.

Kerins A, Koszyczarek M, Smith C, Butler P, Riley R, Madgula V Xenobiotica. 2022; 52(8):904-915.

PMID: 36149349 PMC: 10044449. DOI: 10.1080/00498254.2022.2128468.

References

JOLY J, Doyon C, Peasant Y . Cytochrome P-450 measurement in rat liver homogenate and microsomes. Its use for correction of microsomal losses incurred by differential centrifugation. Drug Metab Dispos. 1975; 3(6):577-86. View

Lipscomb J, Teuschler L, Swartout J, Striley C, Snawder J . Variance of Microsomal Protein and Cytochrome P450 2E1 and 3A Forms in Adult Human Liver. Toxicol Mech Methods. 2009; 13(1):45-51. DOI: 10.1080/15376510309821. View

Rawden H, Carlile D, Tindall A, Hallifax D, Galetin A, Ito K . Microsomal prediction of in vivo clearance and associated interindividual variability of six benzodiazepines in humans. Xenobiotica. 2005; 35(6):603-25. DOI: 10.1080/00498250500162870. View

Baarnhielm C, Dahlback H, Skanberg I . In vivo pharmacokinetics of felodipine predicted from in vitro studies in rat, dog and man. Acta Pharmacol Toxicol (Copenh). 1986; 59(2):113-22. DOI: 10.1111/j.1600-0773.1986.tb00142.x. View

Ito K, Houston J . Comparison of the use of liver models for predicting drug clearance using in vitro kinetic data from hepatic microsomes and isolated hepatocytes. Pharm Res. 2004; 21(5):785-92. DOI: 10.1023/b:pham.0000026429.12114.7d. View

Omura T, Sato R . THE CARBON MONOXIDE-BINDING PIGMENT OF LIVER MICROSOMES. I. EVIDENCE FOR ITS HEMOPROTEIN NATURE. J Biol Chem. 1964; 239:2370-8. View

Subrahmanyam V, Renwick A, Walters D, Young P, Price R, Tonelli A . Identification of cytochrome P-450 isoforms responsible for cis-tramadol metabolism in human liver microsomes. Drug Metab Dispos. 2001; 29(8):1146-55. View

Hamamoto I, Tanaka S, Maeba T, Chikaishi K, Ichikawa Y . Microsomal cytochrome P-450-linked monooxygenase systems and lipid composition of human hepatocellular carcinoma. Br J Cancer. 1989; 59(1):6-11. PMC: 2246956. DOI: 10.1038/bjc.1989.3. View

Schmucker D, Woodhouse K, Wang R, Wynne H, James O, McManus M . Effects of age and gender on in vitro properties of human liver microsomal monooxygenases. Clin Pharmacol Ther. 1990; 48(4):365-74. DOI: 10.1038/clpt.1990.164. View

10.

Iwatsubo T, Hirota N, Ooie T, Suzuki H, Shimada N, Chiba K . Prediction of in vivo drug metabolism in the human liver from in vitro metabolism data. Pharmacol Ther. 1997; 73(2):147-71. DOI: 10.1016/s0163-7258(96)00184-2. View

11.

Johnson T, Tucker G, Tanner M, Rostami-Hodjegan A . Changes in liver volume from birth to adulthood: a meta-analysis. Liver Transpl. 2005; 11(12):1481-93. DOI: 10.1002/lt.20519. View

12.

Edwards R, Adams D, WATTS P, Davies D, Boobis A . Development of a comprehensive panel of antibodies against the major xenobiotic metabolising forms of cytochrome P450 in humans. Biochem Pharmacol. 1998; 56(3):377-87. DOI: 10.1016/s0006-2952(98)00033-1. View

13.

Ito K, Iwatsubo T, Kanamitsu S, Nakajima Y, Sugiyama Y . Quantitative prediction of in vivo drug clearance and drug interactions from in vitro data on metabolism, together with binding and transport. Annu Rev Pharmacol Toxicol. 1998; 38:461-99. DOI: 10.1146/annurev.pharmtox.38.1.461. View

14.

Carlile D, Zomorodi K, Houston J . Scaling factors to relate drug metabolic clearance in hepatic microsomes, isolated hepatocytes, and the intact liver: studies with induced livers involving diazepam. Drug Metab Dispos. 1997; 25(8):903-11. View

15.

Lin J, Lu A . Role of pharmacokinetics and metabolism in drug discovery and development. Pharmacol Rev. 1998; 49(4):403-49. View

16.

Ito K, Houston J . Prediction of human drug clearance from in vitro and preclinical data using physiologically based and empirical approaches. Pharm Res. 2005; 22(1):103-12. DOI: 10.1007/s11095-004-9015-1. View

17.

von Bahr C, Groth C, Jansson H, Lundgren G, Lind M, Glaumann H . Drug metabolism in human liver in vitro: establishment of a human liver bank. Clin Pharmacol Ther. 1980; 27(6):711-25. DOI: 10.1038/clpt.1980.102. View

18.

Houston J . Utility of in vitro drug metabolism data in predicting in vivo metabolic clearance. Biochem Pharmacol. 1994; 47(9):1469-79. DOI: 10.1016/0006-2952(94)90520-7. View

19.

Lipscomb J, Fisher J, Confer P, Byczkowski J . In vitro to in vivo extrapolation for trichloroethylene metabolism in humans. Toxicol Appl Pharmacol. 1998; 152(2):376-87. DOI: 10.1006/taap.1998.8485. View

20.

Wilson Z, Rostami-Hodjegan A, Burn J, Tooley A, Boyle J, Ellis S . Inter-individual variability in levels of human microsomal protein and hepatocellularity per gram of liver. Br J Clin Pharmacol. 2003; 56(4):433-40. PMC: 1884378. DOI: 10.1046/j.1365-2125.2003.01881.x. View